Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955874 | 0.84 | RAB9A (0.64) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL5851841 | 0.83 | NPC1 (0.75) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL2658434 | 0.82 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL12749660 | 0.81 | MEN1 (0.62) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL5395363 | 0.81 | PDE10A (0.68) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL14867043 | 0.80 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPSR1ALDH1A1GAA | |
| SCHEMBL3452939 | 0.80 | ELANE (0.74) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL3314924 | 0.80 | PDE10A (0.71) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL1752742 | 0.80 | NPC1 (0.75) | SMN1; SMN2NPC1RAB9ANPSR1PKM | |
| SCHEMBL5851837 | 0.80 | NPC1 (0.75) | SMN1; SMN2NPC1RAB9ANPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109714-A1 | Transition metal mediated process | ABBOTT GMBH & CO. KG (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20030009034-A1 | Transition metal mediated process | ABBOTT GMBH & CO. KG (DE) | 2003-01-09 | — | — | US | disclosed |
| WO-2002076960-A1 | TRANSITION METAL MEDIATED PROCESS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009034-A1 | Transition metal mediated process | TPMT, ABAT, TFAM | SMN1; SMN2 2129/4885NPC1 3722/4885RAB9A 2973/4885 |
| US-20030109714-A1 | Transition metal mediated process | TPMT, ABAT, TFAM | SMN1; SMN2 2129/4885NPC1 3722/4885RAB9A 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.